Hairy cell leukemia

Clinical effects of the methanol extraction residue (MER) of BCG, lithium carbonate and mononuclear cell-enriched leukocyte transfusions

Jorge R. Quesada, Evan M Hersh, Micheal Keating, Axel Zander, Jeane Hester

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The effect of MER, lithium carbonate or mononuclear cell-enriched leukocyte transfusions was investigated in eleven patients with hairy cell leukemia. These therapeutic modalities were intended to enhance hematopoiesis and restore the immune abnormalities which occur in these patients. Treatment programs consisted of either MER (0.1-0.5 mg/m2 i.v. weekly) or one to two series of three consecutive mononuclear cell transfusions (MNCT), each transfusion containing a mean of 10.6 ± 1.5 × 109 cells/mm3 (8.4 ± 2.9 × 109 lymphocytes and 1.96 ± 1.5 × 109 monocytes) or both. A number of patients were given lithium carbonate followed by MER and then lithium with MER on alternate weeks. A complete hematologic response (CHR) was defined as: hemoglobin above 12 g/dl; neutrophil count > 1500 cells/mm3 and platelet count of > 100,000 mm3. A partial hemotological response (PHR) was defined as recovery of at least two of these parameters. Two CHR and two PHR were seen in patients who received MNCT. Three additional patients who received MER or lithium-MER showed improvement in one hematological parameter. The incidence of infection was significantly lower in the patients who responded to treatment than in those who did not (p < 0.04). Biological stimulation with allogenic cells improved bone marrow failure in patients with HCL. It is expected that hematological recovery and a decrease in the incidence of infections will result in prolonged survival for patients. The contribution of immunoadjuvants or pharmacological agents such as lithium to this therapeutic approach in HCL or other leukemic states where chemotherapy is not desirable requires further investigation.

Original languageEnglish (US)
Pages (from-to)463-476
Number of pages14
JournalLeukemia Research
Volume5
Issue number6
DOIs
StatePublished - 1981
Externally publishedYes

Fingerprint

Leukocyte Transfusion
Lithium Carbonate
Hairy Cell Leukemia
Mycobacterium bovis
Methanol
Lithium
Immunologic Adjuvants
Incidence
Hematopoiesis
Therapeutics
Infection
Platelet Count
Bone Marrow Cells
Monocytes
Hemoglobins
Neutrophils
Cell Count
Pharmacology
Lymphocytes
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Hairy cell leukemia : Clinical effects of the methanol extraction residue (MER) of BCG, lithium carbonate and mononuclear cell-enriched leukocyte transfusions. / Quesada, Jorge R.; Hersh, Evan M; Keating, Micheal; Zander, Axel; Hester, Jeane.

In: Leukemia Research, Vol. 5, No. 6, 1981, p. 463-476.

Research output: Contribution to journalArticle

@article{467d9b9296fe43489a090abf8a6c99ef,
title = "Hairy cell leukemia: Clinical effects of the methanol extraction residue (MER) of BCG, lithium carbonate and mononuclear cell-enriched leukocyte transfusions",
abstract = "The effect of MER, lithium carbonate or mononuclear cell-enriched leukocyte transfusions was investigated in eleven patients with hairy cell leukemia. These therapeutic modalities were intended to enhance hematopoiesis and restore the immune abnormalities which occur in these patients. Treatment programs consisted of either MER (0.1-0.5 mg/m2 i.v. weekly) or one to two series of three consecutive mononuclear cell transfusions (MNCT), each transfusion containing a mean of 10.6 ± 1.5 × 109 cells/mm3 (8.4 ± 2.9 × 109 lymphocytes and 1.96 ± 1.5 × 109 monocytes) or both. A number of patients were given lithium carbonate followed by MER and then lithium with MER on alternate weeks. A complete hematologic response (CHR) was defined as: hemoglobin above 12 g/dl; neutrophil count > 1500 cells/mm3 and platelet count of > 100,000 mm3. A partial hemotological response (PHR) was defined as recovery of at least two of these parameters. Two CHR and two PHR were seen in patients who received MNCT. Three additional patients who received MER or lithium-MER showed improvement in one hematological parameter. The incidence of infection was significantly lower in the patients who responded to treatment than in those who did not (p < 0.04). Biological stimulation with allogenic cells improved bone marrow failure in patients with HCL. It is expected that hematological recovery and a decrease in the incidence of infections will result in prolonged survival for patients. The contribution of immunoadjuvants or pharmacological agents such as lithium to this therapeutic approach in HCL or other leukemic states where chemotherapy is not desirable requires further investigation.",
author = "Quesada, {Jorge R.} and Hersh, {Evan M} and Micheal Keating and Axel Zander and Jeane Hester",
year = "1981",
doi = "10.1016/0145-2126(81)90117-X",
language = "English (US)",
volume = "5",
pages = "463--476",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Hairy cell leukemia

T2 - Clinical effects of the methanol extraction residue (MER) of BCG, lithium carbonate and mononuclear cell-enriched leukocyte transfusions

AU - Quesada, Jorge R.

AU - Hersh, Evan M

AU - Keating, Micheal

AU - Zander, Axel

AU - Hester, Jeane

PY - 1981

Y1 - 1981

N2 - The effect of MER, lithium carbonate or mononuclear cell-enriched leukocyte transfusions was investigated in eleven patients with hairy cell leukemia. These therapeutic modalities were intended to enhance hematopoiesis and restore the immune abnormalities which occur in these patients. Treatment programs consisted of either MER (0.1-0.5 mg/m2 i.v. weekly) or one to two series of three consecutive mononuclear cell transfusions (MNCT), each transfusion containing a mean of 10.6 ± 1.5 × 109 cells/mm3 (8.4 ± 2.9 × 109 lymphocytes and 1.96 ± 1.5 × 109 monocytes) or both. A number of patients were given lithium carbonate followed by MER and then lithium with MER on alternate weeks. A complete hematologic response (CHR) was defined as: hemoglobin above 12 g/dl; neutrophil count > 1500 cells/mm3 and platelet count of > 100,000 mm3. A partial hemotological response (PHR) was defined as recovery of at least two of these parameters. Two CHR and two PHR were seen in patients who received MNCT. Three additional patients who received MER or lithium-MER showed improvement in one hematological parameter. The incidence of infection was significantly lower in the patients who responded to treatment than in those who did not (p < 0.04). Biological stimulation with allogenic cells improved bone marrow failure in patients with HCL. It is expected that hematological recovery and a decrease in the incidence of infections will result in prolonged survival for patients. The contribution of immunoadjuvants or pharmacological agents such as lithium to this therapeutic approach in HCL or other leukemic states where chemotherapy is not desirable requires further investigation.

AB - The effect of MER, lithium carbonate or mononuclear cell-enriched leukocyte transfusions was investigated in eleven patients with hairy cell leukemia. These therapeutic modalities were intended to enhance hematopoiesis and restore the immune abnormalities which occur in these patients. Treatment programs consisted of either MER (0.1-0.5 mg/m2 i.v. weekly) or one to two series of three consecutive mononuclear cell transfusions (MNCT), each transfusion containing a mean of 10.6 ± 1.5 × 109 cells/mm3 (8.4 ± 2.9 × 109 lymphocytes and 1.96 ± 1.5 × 109 monocytes) or both. A number of patients were given lithium carbonate followed by MER and then lithium with MER on alternate weeks. A complete hematologic response (CHR) was defined as: hemoglobin above 12 g/dl; neutrophil count > 1500 cells/mm3 and platelet count of > 100,000 mm3. A partial hemotological response (PHR) was defined as recovery of at least two of these parameters. Two CHR and two PHR were seen in patients who received MNCT. Three additional patients who received MER or lithium-MER showed improvement in one hematological parameter. The incidence of infection was significantly lower in the patients who responded to treatment than in those who did not (p < 0.04). Biological stimulation with allogenic cells improved bone marrow failure in patients with HCL. It is expected that hematological recovery and a decrease in the incidence of infections will result in prolonged survival for patients. The contribution of immunoadjuvants or pharmacological agents such as lithium to this therapeutic approach in HCL or other leukemic states where chemotherapy is not desirable requires further investigation.

UR - http://www.scopus.com/inward/record.url?scp=0019843476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019843476&partnerID=8YFLogxK

U2 - 10.1016/0145-2126(81)90117-X

DO - 10.1016/0145-2126(81)90117-X

M3 - Article

VL - 5

SP - 463

EP - 476

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 6

ER -